Table 4.
Comparison of demographic, clinical, and laboratory screening variables at the end of three months.
Survivors (n =26) | Nonsurvivors (n = 22) | p value | |
| |||
Demographic | |||
Age | 55.3 (±12.1) | 54.1 (±9.5) | 0.726 |
Men | 17 (65.4%) | 16 (72.7%) | 0.584 |
Women | 9 (34.6%) | 6 (33.3%) | |
Clinical | |||
Child-Pugh | 9.7(±2.1) | 10.9(±1.8) | 0.046 |
MELD | 19.3 (±6.1) | 24.6 (±7.6) | 0.012 |
MELD-Na | 21.7 (±6.6) | 27.5 (± 6.2) | 0.03 |
ICA-AKI Stage | |||
1 | 17 (65.4%) | 10 (56.3%) | 0.259 |
2 | 6 (23.1%) | 10 (45.5%) | |
3 | 3 (11.5%) | 2 (9.1%) | |
Subdivision of stage 1 (n=28) | |||
1a | 5 (29.4%) | 2 (20%) | 0.678 |
1b | 12 (70.6%) | 8 (80%) | |
AKI causes | |||
Infection | 10 (38.5%) | 10 (45.5%) | 0.058 |
Hypovolemia | 9 (34.6%) | 6 (27.3%) | |
Hepatorenal syndrome | 0 | 4 (18.2%) | |
Nephropathy | 2 (7.7%) | 0 | |
Miscellaneous | 1 (3.8%) | 2 (9.1%) | |
Multiple | 4 (15.4%) | 0 | |
Response to expansion treatment | <0.0001 | ||
Complete | 20 (76.9%) | 7 (31.8%) | |
Partial | 5 (19.2%) | 3 (13.6%) | |
Absent | 1 (3.8%) | 12 (54.5%) | |
Encephalopathy | |||
Present | 6 (23.1%) | 7 (31.8%) | 0.361 |
Absent | 20 (76.9%) | 15 (68.2%) | |
Ascites | |||
Present | 21 (80.8%) | 12 (90.9%) | 0.532 |
Absent | 5 (19.2%) | 2 (9.1%) | |
Laboratory | |||
Creatinine (mg/dL) | 2.0(±0.9) | 2.2(±2.2) | 0.525 |
Total bilirrubin (mg/dL) | 1.6 (0.3-15.2) | 5 (0.4-23.9) | 0.020 |
Albumin (g/dL) | 2.4 (±0.5) | 2.6 (±0.5) | 0.368 |
INR | 1.5(1-3) | 1.9(1.1-7) | 0.067 |
Sodium (mEq/L) | 134.1 (±5.2) | 133.4 (±5.2) | 0.681 |
C-Reactive Protein (mg/L) | 30.4 (5-278) | 31.6(5-278) | 0.869 |
ICA-AKI, International Club of Ascites–Acute Kidney Injury.